Indian drugmaker Dr Reddy’s Laboratories Ltd. is planning to launch a generic version of Novo Nordisk A/S’s Ozempic in March ...
Dr. Reddy’s Laboratories has released its financial results for the third quarter of fiscal year 2026. The pharmaceutical company reported a modest revenue increase but fell short of market ...
Dr Reddy's Laboratories Ltd (RDY) reports steady revenue growth driven by emerging markets and strategic collaborations, ...
Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2026 Earnings Call Transcript January 21, 2026 Dr. Reddy’s Laboratories ...
Dr Reddy’s Laboratories reported Q3 net profit of ₹1,209 crore, beating estimates, while revenue and EBITDA also came in above expectations, though on a year-on-year basis, profit and EBITDA declined ...
Dr Reddy Laboratories Share Price Jumps Nearly 6% After Q3 FY26 Net Profit Falls 14.4% YoY; Should You Buy This Pharma Stock?
Stay informed with the Dr Reddys Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of a ...
Brokerages said Dr Reddy's Laboratories Q3 FY26 earnings beat was driven largely by the domestic and emerging markets portfolio, which helped offset weakness in the US.
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), and its ...
Dr Reddy's Laboratories share price jumps nearly 5% after Q3 results; revenue rises 4%, profit dips 14% YoY as brokerages ...
Dr. Reddy's Laboratories Ltd. closed 16.14% below its 52-week high of 1,377.95 rupees, which the company reached on June 12th ...
The total revenue of the Hyderabad based company grew 4.4% at ₹8,726 crore against ₹8,358 crore in the same period last year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results